Compare · ARGX vs SLXN
ARGX vs SLXN
Side-by-side comparison of argenx SE (ARGX) and Silexion Therapeutics Corp (SLXN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and SLXN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $56.09B, about 19540.5x SLXN ($2.9M).
- Over the past year, ARGX is up 72.0% and SLXN is down 97.7% - ARGX leads by 169.7 points.
- SLXN has been more active in the news (10 items in the past 4 weeks vs 4 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 0 for SLXN).
- Company
- argenx SE
- Silexion Therapeutics Corp
- Price
- $932.21+3.05%
- $2.81-2.93%
- Market cap
- $56.09B
- $2.9M
- 1M return
- +14.16%
- -41.57%
- 1Y return
- +71.96%
- -97.69%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 4
- 10
- Recent ratings
- 25
- 0
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
Latest SLXN
- Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
- SEC Form EFFECT filed by Silexion Therapeutics Corp
- SEC Form 424B3 filed by Silexion Therapeutics Corp
- SEC Form DEF 14A filed by Silexion Therapeutics Corp
- Silexion Therapeutics to Attend BIO International Convention 2026
- SEC Form S-3 filed by Silexion Therapeutics Corp
- CSO and CDO Shirvan Mitchell was granted 6,000 units of Ordinary Shares, increasing direct ownership by 215% to 8,789 units (SEC Form 4)
- CFO and Secretary Horenshtein Hadar Mirit was granted 7,500 units of Ordinary Shares, increasing direct ownership by 150% to 12,515 units (SEC Form 4)
- Chairman and CEO Hadar Ilan was granted 10,000 units of Ordinary Shares, increasing direct ownership by 153% to 16,547 units (SEC Form 4)
- SEC Form PRE 14A filed by Silexion Therapeutics Corp